Cal, this has to be good for Pennsaid.
It looks like the PP is underway, with Canaccord selling into the price appreciation.
There are still legacy issues to be resolved for Pennsaid (eg., prejudice against topicals for OA, no US market as of yet, chronically underfunded marketing, more trials needed, etc) but this news couldn't have come at a better time.
"Mr. Chicoine said Dimethaid's goal must be to better promote the licensing of Pennsaid and get the product to market as fast as possible in as many markets as possible."
Right from the beginning, Dan Chicoine stated the necessity of getting Pennsaid to market. Not, as some chose to portray it, an effort to sidetrack Pennsaid in favour of WF10.
The Vioxx news (which really applies to all Cox2 inhibitors) will finally give some weight to the longstanding (but unsubstantiated through lack of data) argument that Pennsaid is a preferable alternative, actually cost-effective in the long run.
MHOs, insurers take note.
Dimethaid still faces obstacles, and some big unknowns, but this is encouraging.
Jim |
